Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Shares Shorted: Short Interest Down 60.8% in September

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) was the recipient of a significant decrease in short interest in September. As of September 30th, there was short interest totaling 13,598 shares, a decrease of 60.8% from the September 15th total of 34,666 shares. Currently, 1.0% of the shares of the stock are short sold. Based on an average trading volume of 32,535 shares, the days-to-cover ratio is presently 0.4 days.

Aspire Biopharma Price Performance

NASDAQ:ASBP traded up $0.12 on Wednesday, reaching $8.29. The stock had a trading volume of 5,006 shares, compared to its average volume of 281,687. The company has a market cap of $11.61 million, a price-to-earnings ratio of -0.12 and a beta of 0.17. The firm’s fifty day moving average is $8.32 and its two-hundred day moving average is $9.50. Aspire Biopharma has a 12-month low of $3.31 and a 12-month high of $562.92.

Analyst Ratings Changes

Separately, Weiss Ratings cut shares of Aspire Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, September 25th. One research analyst has rated the stock with a Sell rating. According to MarketBeat, Aspire Biopharma has an average rating of “Sell”.

About Aspire Biopharma

Aspire Biopharma, Inc is a biotechnology company focused on developing rapid drug-delivery technologies and pharmaceutical products. The company’s platform is designed to administer medications through the sublingual and buccal tissues of the mouth, with the goal of enabling faster absorption than conventional oral tablets.

Aspire Biopharma’s lead product candidate is an orally delivered, fast-acting aspirin formulation intended for potential use in cardiovascular emergencies and other situations in which rapid aspirin administration may be beneficial.